Compugen Stock Today
| CGEN Stock | USD 1.67 0.04 2.34% |
PerformanceSoft
| Odds Of DistressLow
|
Compugen is selling at 1.67 as of the 14th of February 2026; that is 2.34% down since the beginning of the trading day. The stock's open price was 1.71. Compugen has less than a 11 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. The performance scores are derived for the period starting the 16th of November 2025 and ending today, the 14th of February 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 11th of August 2000 | Category Healthcare | Classification Health Care |
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel. The company has 93.54 M outstanding shares of which 979.33 K shares are currently shorted by private and institutional investors with about 1.73 trading days to cover. More on Compugen
Moving together with Compugen Stock
Moving against Compugen Stock
Compugen Stock Highlights
| President CEO, Director | Anat CohenDayag | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Life Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Life Sciences Tools & Services, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCompugen utilizes debt financing to potentially enhance returns on invested capital. The relationship between total debt and total assets provides valuable insight into Compugen's leverage profile, showing how much of Compugen's resources are funded through borrowing.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Compugen (CGEN) is traded on NASDAQ Exchange in USA and employs 74 people. Compugen is listed under Life Sciences Tools & Services category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 155.32 M. Compugen conducts business under Life Sciences Tools & Services sector and is part of Health Care industry. The entity has 93.54 M outstanding shares of which 979.33 K shares are currently shorted by private and institutional investors with about 1.73 trading days to cover.
Compugen currently holds about 88.21 M in cash with 49.6 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.02.
Check Compugen Probability Of Bankruptcy
Ownership AllocationCompugen holds a total of 93.54 Million outstanding shares. Almost 84.26 percent of Compugen outstanding shares are held by general public with 2.02 (percent) owned by insiders and only 13.72 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Compugen Ownership Details
Compugen Historical Income Statement
Compugen Stock Against Markets
Compugen Corporate Management
| Zurit Levine | VP of Research and Discovery | Profile | |
| Alberto Sessa | Chief Officer | Profile | |
| Rivka Schwartz | Vice Discovery | Profile | |
| Henry MD | Senior Officer | Profile | |
| Eran Ophir | Chief Officer | Profile | |
| Michelle MD | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Compugen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in discontinued. To learn how to invest in Compugen Stock, please use our How to Invest in Compugen guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Will Life Sciences Tools & Services sector continue expanding? Could Compugen diversify its offerings? Factors like these will boost the valuation of Compugen. Projected growth potential of Compugen fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Compugen data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.30) | Revenue Per Share | Quarterly Revenue Growth (0.89) | Return On Assets | Return On Equity |
Investors evaluate Compugen using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Compugen's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Compugen's market price to deviate significantly from intrinsic value.
It's important to distinguish between Compugen's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Compugen should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Compugen's market price signifies the transaction level at which participants voluntarily complete trades.